Anti-thrombotic and anti-coagulation effects of direct oral anticoagulants (DOACs) are dose-dependent [1–5]. Conversely, the benefit from higher dose DOACs is counterbalanced by a dose-dependent risk of bleeding [4]. Currently recommended regimens are the result of pre-clinical [5,6] and phase III studies [1,2,7–12] in which various doses of DOACs were investigated and compared to standard of care in various conditions such as acute or stable coronary artery disease (CAD), peripheral artery disease (PAD), non-valvular atrial fibrillation (AF), and venous thromboembolism (VTE).
